US FDA commissioner's hammer falls on Avastin; breast cancer use revoked

US Food and Drug Administration commissioner Margaret Hamburg has rescinded the agency's approval for Genentech's Avastin (bevacizumab) as a treatment for HER2-negative metastatic breast cancer (MBC), after deciding that follow-up studies had failed to show that the drug is a safe and effective therapy for the disease1.